BMJ 2013-12-01

Role of diuretics, _ blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.

Lan Shen, BimalR Shah, EricM Reyes, Laine Thomas, Daniel Wojdyla, Peter Diem, LawrenceA Leiter, Bernard Charbonnel, Viacheslav Mareev, EdwardS Horton, StevenM Haffner, Vladimir Soska, Rury Holman, MAngelyn Bethel, Frank Schaper, Jie-Lena Sun, JohnJV McMurray, RobertM Califf, Henry Krum

Index: BMJ 347 , f6745, (2013)

Full Text: HTML

Abstract

To examine the degree to which use of _ blockers, statins, and diuretics in patients with impaired glucose tolerance and other cardiovascular risk factors is associated with new onset diabetes.

Related Compounds

  • Nateglinide
  • L-Valine
  • L-Phenylalanine
  • Valsartan
  • D-Phenylalanine,...

Related Articles:

Formulation and in vitro evaluation of nateglinide microspheres using HPMC and carbopol-940 polymers by ionic gelation method.

2013-11-01

[Pak. J. Pharm. Sci. 26(6) , 1229-35, (2013)]

From evidence assessments to coverage decisions?: the case example of glinides in Germany.

2012-01-01

[Health Policy 104(1) , 27-31, (2012)]

Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.

2005-10-01

[Int. J. Clin. Pract. 59(10) , 1218-28, (2005)]

Efficacy and safety of mitiglinide versus nateglinide in newly diagnose patients with type 2 diabetes mellitus: a randomized double blind trial.

2012-02-01

[Diabetes Obes. Metab. 14(2) , 187-9, (2012)]

Nateglinide (Starlix): update on a new antidiabetic agent.

2003-01-01

[Int. J. Clin. Pract. 57(6) , 535-41, (2003)]

More Articles...